Subscribe Now Subscribe Today
Editorial
 

A Comparison between the use and Availability of Antidotes in Iran and United States of America



Shahin Shadnia and Fiona M. Garlich
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
ABSTRACT

Not Available

Services
Related Articles in ASCI
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

Shahin Shadnia and Fiona M. Garlich, 2011. A Comparison between the use and Availability of Antidotes in Iran and United States of America. International Journal of Pharmacology, 7: 799-800.

DOI: 10.3923/ijp.2011.799.800

URL: https://scialert.net/abstract/?doi=ijp.2011.799.800
 
Received: July 28, 2011; Accepted: October 01, 2011; Published: December 27, 2011



We read with great interest Nikfar et al. (2011) article entitled “Cost and Utilization Study of Antidotes: An Iranian Experience”. In this regard we made a comparison between the use and availability of antidotes in Iran and United States of America (U.S.).

The use of a specific antidote was reported to US Poison Centers approximately 83,000 times in 2009 (Bronstein et al., 2010). While this data is severely limited by underreporting, it does illustrate that the use of expensive, specialized antidotes such as fomepizole is quite commonplace in the U.S. for the treatment of suspected toxic alcohol poisoning. As a comparison, the administration of ethanol for this indication was reported only 96 times. Additionally, the use of digoxin-specific Fab fragments is routine in U.S. hospitals for the treatment of patients with confirmed or suspected digoxin toxicity (DiDomenico et al., 2000). In contrast, fomepizole and digoxin-specific Fab fragments are registered in Iranian Drug List (Nikfar et al., 2005), but they are not present in the market.

The World Health Organization (WHO) guidelines for Poison Control Centers recommend that all antidotes needed within 30 min should be stocked at all hospitals (WHO, 1997). The availability of antidotes has been repeatedly found to be inadequate in hospitals in North America (Howland et al., 1986; Dart et al., 1996, 2000; Juurlink et al., 2001; Wiens et al., 2006). Factors associated with poor antidote stocking included small hospital size, rural location and isolation from other hospitals (Wiens et al., 2006).

Studies in the United Kingdom (Higgins and Evans, 2000) and South Africa (Wium and Hoffman, 2009) have also demonstrated insufficient availability of essential antidotes in a timely fashion, and a lack of awareness of recommended stocking guidelines.

In 2009, an expert consensus panel was formed to make recommendations for stocking of antidotes at US hospitals. Twenty-four antidotes were recommended for stocking at all hospitals, 12 of which should be available for administration immediately upon patient arrival. An additional 9 antidotes were recommended to be available within one hour of the decision to administer the antidote (Dart et al., 2009).

In contrast, the availability of antidotes in Iran is limited to one or two referral hospitals in each province that are specialized in the management of poisoned patients. In these hospitals, clinical toxicologist or trained clinicians direct the management of poisoned patients. This regionalization of antidote stocks may prevent the misuse or overuse of expensive antidotes by inexperienced clinicians, but it also may result in critical delay of care for patients who present to other hospitals in the region.

To our knowledge, there are no national guidelines for antidote stocking in Iran and the study by Nikfar et al. (2011) is the first to examine the availability of antidotes in this country (Nikfar et al., 2011).

The availability and supply of antidotes presents challenges in Iran, as well as in the U.S. We suspect that similar problems may be encountered in other countries.

REFERENCES

  1. Bronstein, A.C., D.A. Spyker, L.R. Cantilena, J.L. Green, B.H. Rumack and S.L. Giffin, 2010. Annual report of the American association of poison control centers national poison data system (NPDS): 27th annual report. Clin. Toxicol., 48: 979-1178.


  2. Dart, R.C., Y. Stark, B. Fulton, J. Koziol-McLain and S.R. Lowenstein, 1996. Insufficient stocking of poisoning antidotes in hospital pharmacies. J. Amer. Med. Assoc., 276: 1508-1510.
    CrossRef  |  


  3. Dart, R.C., L.R. Goldfrank, P.A. Chyka, D. Lotzer and A.D. Woolf et al., 2000. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann. Emerg. Med., 36: 126-132.
    Direct Link  |  


  4. Dart, R.C., S.W. Borron and E.M. Caravati, 2009. Antidote summit authorship group: Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann. Emerg. Med., 54: 386-394.


  5. DiDomenico, R.J., S.M. Walton, C.A. Sanoski and J.L. Bauman, 2000. Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity. J. Cardiovasc. Pharmacol. Ther., 5: 77-85.
    CrossRef  |  


  6. Higgins, M.A. and R. Evans, 2000. Antidotes inappropriate timely availability. Hum. Exp. Toxicol., 19: 485-488.
    CrossRef  |  


  7. Nikfar, S., M. Khatibi, A. Abdollahi-Asl and M. Abdollahi, 2011. Cost and utilization study of antidotes: An Iranian experience. Int. J. Pharmacol., 7: 46-49.
    CrossRef  |  Direct Link  |  


  8. Nikfar, S., A. Kebriaeezadeh, R. Majdzadeh and M. Abdollahi, 2005. Monitoring of National Drug Policy (NDP) and its standardized indicators conformity to decisions of the national drug selecting committee in Iran. BMC Int. Health Hum. Rights, 5: 5-5.
    CrossRef  |  Direct Link  |  


  9. Wium, C.A. and B.A. Hoffman, 2009. Antidotes and their availability in South Africa. Clin. Toxicol., 47: 77-80.
    PubMed  |  


  10. WHO, 1997. Guidelines for poison control centers. World Health Organization Geneva, http://www.who.int/publications/en/.


  11. Howland, M.A., R. Weisman, D. Sauter and L. Goldfrank, 1986. Nonavailability of poison antidotes. N. Engl. J. Med., 314: 927-928.


  12. Juurlink, D.N., M.A. McGuigan, T.W. Paton and D.A. Redelmeier, 2001. Availability of antidotes at acute care hospitals in Ontario. Can. Med. Assoc. J., 165: 27-30.
    Direct Link  |  


  13. Wiens, M.O., P.J. Zed, K.J. Lepik, R.B. Abu-Laban and J.R. Brubacher et al., 2006. Adequacy of antidote stocking in British Columbia hospitals: The 2005 antidote stocking study. Can. J. Emerg. Med., 8: 409-416.
    PubMed  |  Direct Link  |  


©  2022 Science Alert. All Rights Reserved